Category - Markets

Markets

Roth starts CRISPR Therapeutics at buy; PT $50

Roth Capital Partners initiated coverage of CRISPR Therapeutics PLC (NASDAQ:CRSP) with a “buy” rating and $50 price target. The stock closed at $44.38, up $1.50, on June 10.

June 11, 2019

Markets

HCW ups Sesen Bio to buy; PT to $3

H.C. Wainwright upgraded Sesen Bio (NASDAQ:SESN) to “buy” from “neutral” and raised its price target to $3 from $1 after the company had a successful Type B pre-biologics license application (BLA) meeting with FDA for...

June 11, 2019

Markets

Roth starts Intellia Therapeutics at neutral; PT $16

Roth Capital Partners launched coverage of Intellia Therapeutics (NASDAQ:NTLA) with a “neutral” rating and $16 price target, saying the stock is fully valued ahead of first-in-human studies. The stock closed at $14.36...

June 11, 2019

Markets

SVB Leerink cuts InflaRx to MP from OP; PT to $4 from $67

SVB Leerink downgraded German drug maker InflaRx (NASDAQ:IFRX) to “market perform” from “outperform” and slashed its price target to $4 from $67 after its lead drug failed to benefit patients with a debilitating skin...

June 5, 2019

Markets

Analysts start Trevi Therapeutics at OP, buy; PTs $14, $20

SVB Leerink launched coverage of Trevi Therapeutics (NASDAQ:TRVI) with an “outperform” rating and $14 price target. The stock closed at $9.99 on May 31.

June 4, 2019

Markets

SVB Leerink starts Axcella Health at OP; PT $21

SVB Leerink initiated coverage of Axcella Health (NASDAQ:AXLA) with an “outperform” rating and a $21 price target. The stock closed at $14.27 on May 31.

June 3, 2019

Markets

Roth starts Atara Biotherapeutics at buy; PT $30

Roth Capital Partners launched coverage of Atara Biotherapeutics (NASDAQ:ATRA) with a “buy” rating and price target of $30. The stock closed at $23.30 on May 29.

May 31, 2019

Markets

Roth starts Marker Therapeutics at buy; PT $10

Roth Capital Partners initiated coverage of Marker Therapeutics (NASDAQ:MRKR) with a “buy” rating and $10 price target. The stock closed at $5.91 on May 29.

May 31, 2019

Markets

Roth starts Forty Seven at buy; PT $28

Roth Capital Partners initiated coverage of Forty Seven (NASDAQ:FTSV) with a “buy” rating and $28 price target. The stock closed at $12.49, up 34 cents, on May 28.

May 29, 2019

Markets

Roth starts Five Prime Therapeutics at neutral; PT $10

Roth Capital Partners launched coverage of Five Prime Therapeutics (NASDAQ:FPRX) with a “neutral” rating and $10 price target. The stock closed at $8.73, down 32 cents, on May 28.

May 29, 2019

Category - Markets

Subscribe